When did Regenxbio report Q1 2026 earnings?

Regenxbio (RGNX) reported Q1 2026 earnings on May 14, 2026 before market open.

What were Regenxbio's Q1 2026 revenue and EPS?

Regenxbio reported revenue of $6.4M and eps of $-1.72 for Q1 2026.

Did Regenxbio beat estimates in Q1 2026?

Revenue missed the consensus estimate of $25.8M by $19.4M. EPS missed the consensus estimate of $-1.36 by $0.36.

How did Regenxbio's Q1 2026 results compare year-over-year?

Compared to the same quarter a year prior, revenue declined 92.8% from $89.0M a year earlier.

Where can I find Regenxbio's Q1 2026 SEC filings?

You can read the 8-K earnings release (0001193125-26-222768) and the 10-Q periodic report (0001193125-26-222804) directly on SEC EDGAR. The filing index links above go to sec.gov.

Regenxbio RGNX Q1 2026 earnings

Reported May 14, 2026 · Before market open

Revenue$6.4MMiss by $19.4M

EPS-$1.72Miss by $0.36

Revenue estimate$25.8M

EPS estimate-$1.36

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$97.6M

EPS estimate$0.12

Financials

Q1 2026

Income statement

See full

Revenue$6.4M-92.8%

Operating income-$83.4M-787%

Net income-$90.1M-1,580%

EPS (diluted)-$1.72-1,533%

Balance sheet

See full

Cash & equivalents$15.2M-88.3%

Total debt$71.1M-11.0%

Total equity$21.1M-92.3%

Total assets$341.9M-30.4%

Cash flow

See full

Operating cash flow-$76.2M-327%

CapEx$1.2M+20.6%

Free cash flow-$77.4M-337%

Valuation & ratios

Valuation

as of 07/28/26

See full

Market cap$621.64M+40.4%

Enterprise value$677.47M+53.6%

P/S7.1×+4.2×

Profitability

See full

Operating margin-292.3%-613pp

Net margin-330.2%-588pp

FCF margin-269.2%-364pp

Returns & leverage

See full

Return on equity-196.4%-288pp

Debt / equity3.4×+3.1×

Current ratio2.6×-0.3×

Segments

By product

See full

Zolgensma And Itvisma Royalties$5.1M-70.3%

Total Service Revenue$1.3M-33.6%

Nippon Shinyaku Services$1.0M-43.0%

Other Service Revenue$292.0K+54.5%

Versus estimates

Revenue

Q1 2026$6.4MMiss by $19.4M

Q4 2025$30.3MMiss by $13.6M Q3 2025$29.7MMiss by $29.5M Q2 2025$21.4MMiss by $88.7M Q1 2025$89.0MMiss by $16.3M Q4 2024$21.2MMiss by $2.5M

Diluted EPS

Q1 2026-$1.72Miss by $0.36

Q4 2025-$1.30Miss by $0.29 Q3 2025-$1.20Beat by $0.18 Q2 2025-$1.38Miss by $0.25 Q1 2025$0.12Miss by $0.29 Q4 2024-$1.01Beat by $0.26

Ask the moment Regenxbio reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Regenxbio report Q1 2026 earnings?: Regenxbio (RGNX) reported Q1 2026 earnings on May 14, 2026 before market open.
What were Regenxbio's Q1 2026 revenue and EPS?: Regenxbio reported revenue of $6.4M and eps of $-1.72 for Q1 2026.
Did Regenxbio beat estimates in Q1 2026?: Revenue missed the consensus estimate of $25.8M by $19.4M. EPS missed the consensus estimate of $-1.36 by $0.36.
How did Regenxbio's Q1 2026 results compare year-over-year?: Compared to the same quarter a year prior, revenue declined 92.8% from $89.0M a year earlier.
Where can I find Regenxbio's Q1 2026 SEC filings?: You can read the 8-K earnings release (0001193125-26-222768) and the 10-Q periodic report (0001193125-26-222804) directly on SEC EDGAR. The filing index links above go to sec.gov.